Using platelet aggregation tests to guide antiplatelet treatment in acute ischemic stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional trial enrolls adults with non-disabling acute ischemic stroke (NIHSS ≤5) or high-risk TIA (ABCD2 ≥4) within 48 hours of symptom onset who receive a clopidogrel 300 mg plus aspirin 100 mg loading dose. Platelet aggregation (MARADP) is measured 5–20 hours after loading, and patients with MARADP ≥35%—indicating possible clopidogrel resistance—are assigned to ticagrelor instead of clopidogrel to compare outcomes. The trial tracks recurrent ischemic events and safety outcomes, including bleeding, over the follow-up period. The goal is to determine whether platelet-function-guided switching to ticagrelor improves prevention of recurrent stroke without unacceptable safety risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years old.
2. Patients diagnosed with acute non-disabling ischaemic stroke or transient ischaemic attack (TIA) with moderate to high stroke risk in accordance with the WHO diagnostic criteria, defined as follows:

   * Acute non-disabling ischaemic stroke: NIHSS score ≤ 5 at enrollment;
   * TIA with moderate to high stroke risk: ABCD₂ score ≥ 4.
3. Time from symptom onset ≤ 48 hours. (Definition of symptom onset time: the interval from the last time the patient was observed in a normal state to the time of co-administration of clopidogrel 300 mg and aspirin 100 mg.)
4. MARADP ≥ 35% measured at 5-20 hours after the patient received antiplatelet therapy with co-administration of clopidogrel 300 mg and aspirin 100 mg within 48 hours of symptom onset.
5. Written informed consent signed by the patient or their legal representative.

Exclusion Criteria:

1. Imaging examinations suggestive of hemorrhagic stroke, hemorrhagic transformation, or other pathological cerebral disorders, such as vascular malformation, tumor, abscess, or other common non-ischemic cerebral diseases (e.g., multiple sclerosis).
2. Minor stroke/TIA induced by angioplasty or vascular surgery.
3. Routine electrocardiogram (ECG) suggestive of atrial fibrillation (AF), or physical examination findings of typical AF signs including completely irregular cardiac rhythm, variable intensity of the first heart sound, and pulse deficit.
4. Having definite indications for anticoagulant therapy (suspected cardiogenic embolism, e.g., atrial fibrillation, known artificial heart valve, suspected endocarditis, etc.).
5. Patients who have received intravenous thrombolysis, intra-arterial thrombolysis, mechanical thrombectomy, or any revascularization surgery after the current onset, or plan to receive such procedures within 90 days.
6. Use of antiplatelet agents other than aspirin and clopidogrel (e.g., ticagrelor, prasugrel) within 7 days.
7. History of gastrointestinal bleeding, intracranial hemorrhage, massive hemorrhage or blood transfusion in the recent period (excluding mild hemoptysis and mild abnormal vaginal bleeding), or history of other hemorrhagic diseases caused by coagulation dysfunction (e.g., purpura).
8. Having contraindications to or intolerance of clopidogrel, ticagrelor, or aspirin, including:

   * Known history of hypersensitivity;
   * Severe hepatic or renal insufficiency (definition of severe hepatic insufficiency: ALT \> 2× upper limit of normal \[ULN\] or AST \> 2× ULN; definition of severe renal insufficiency: creatinine \> 1.5× ULN);
   * Severe heart failure (NYHA Class Ⅲ or Ⅳ);
   * Coagulation disorders or history of systemic hemorrhage;
   * History of previous thrombocytopenia or neutropenia;
   * History of previous drug-induced hematological diseases or hepatic dysfunction.
9. Leukopenia (\< 2×10⁹/L) or thrombocytopenia (\< 100×10⁹/L).
10. Use of heparin or oral anticoagulants within 10 days prior to enrollment.
11. Patients with severe cardiac, pulmonary, hepatic, or renal insufficiency, and those with severe comorbidities (e.g., malignancy, chronic airflow limitation, severe dementia, severe heart failure).
12. Women of childbearing age with a negative pregnancy test but who refuse to adopt effective contraceptive measures; pregnant or lactating women.
13. Poor compliance, unable to cooperate with the requirements of the study.

Where it's running

• Sichuan Provincial People's Hospital
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Jie Yang Deputy Director of the Department of Neurology
• Email: yangjie1126@163.com
• Phone: +8613678130516

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short-Term outside-in nerve stimulation for acute ischemic stroke

  This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.

  Recruiting Xidian University · Xi'an · NCT07911605

• Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal

  This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.

  Recruiting Phase 3 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Barcelona · NCT07902791

• Safety of adding NRICM301 to standard care for adults with acute ischemic stroke

  This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.

  Recruiting En Chu Kong Hospital · New Taipei City · NCT07900503

• Intracranial Recanalization with LT3001 in Acute Ischemic Stroke

  This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.

  Recruiting Phase 2 Lumosa Therapeutics Co., Ltd. · Taichung · NCT07890298

• Mobilisation After Endovascular Stroke Treatment

  This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.

  Recruiting at 2 sites Karolinska Institutet · Tampere and 1 other locations · NCT07860333

• Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes

  In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Barcelona · NCT07843797

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.